French drugmaker Sanofi announced on Tuesday its collaboration with artificial intelligence company OpenAI and Formation Bio to advance its drug development projects through the use of Artificial Intelligence (AI).
Sanofi stated that the partnership with OpenAI will grant it access to proprietary data, enabling the development of AI models for its biopharma projects. Formation Bio will contribute additional engineering resources to support these efforts.
The use of AI is becoming increasingly prevalent among major drugmakers. AI technologies are employed to identify suitable patients for clinical trials more rapidly and reduce the number of participants required for testing new medicines. These advancements not only speed up the drug development process but also have the potential to save millions of dollars.
Sanofi's collaboration with OpenAI and Formation Bio underscores its commitment to leveraging cutting-edge technology to enhance drug discovery and development, ultimately aiming to bring new treatments to patients more efficiently.
